Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study

Abstract Domperidone, ondansetron and olanzapine can prolong the QT interval. The clinical use of combinations of these drugs is not uncommon. Our study aimed to determine the presence of any QTc prolonging effect of the combination when used as antiemetic in patients receiving cancer chemotherapy....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ashwin Kamath, K. Maneesh Rai, R. Shreyas, PU Prakash Saxena, Sourjya Banerjee
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/22863393271245d3999513d2007e8060
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:22863393271245d3999513d2007e8060
record_format	dspace
spelling	oai:doaj.org-article:22863393271245d3999513d2007e80602021-12-02T14:12:45ZEffect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study10.1038/s41598-020-79380-12045-2322https://doaj.org/article/22863393271245d3999513d2007e80602021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-79380-1https://doaj.org/toc/2045-2322Abstract Domperidone, ondansetron and olanzapine can prolong the QT interval. The clinical use of combinations of these drugs is not uncommon. Our study aimed to determine the presence of any QTc prolonging effect of the combination when used as antiemetic in patients receiving cancer chemotherapy. We carried out a prospective, observational study of patients with malignancy who were to receive domperidone, ondansetron and olanzapine-containing antiemetic regimen. Electrocardiograms were recorded before and during the administration of antiemetics, for three consecutive days. A blinded assessor determined the QTc interval using Bazett and Fridericia formulae. Thirty-six patients completed the study; 23 (63.9%) were females. There was a statistically significant change in QTc with time (Fridericia, χ2(4) = 15.629, p = 0.004; Bazett, χ2(4) = 15.910, p = 0.003); QTc on Day 1 was more than that during baseline (p < 0.001); these differences were significant in females (Fridericia, χ2(4) = 13.753, p = 0.008; Bazett, χ2 (4) = 13.278, p = 0.010) but not in males (Fridericia, χ2 (4) = 4.419, p = 0.352; Bazett, χ2(4) = 4.280, p = 0.369). Two female patients had an absolute QTc prolongation (Bazett correction) of > 500 ms. However, no clinically significant adverse events occurred. The findings show that QTc prolongation is a concern with olanzapine alone and in combination with domperidone and ondansetron, and needs to be investigated further.Ashwin KamathK. Maneesh RaiR. ShreyasPU Prakash SaxenaSourjya BanerjeeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ashwin Kamath K. Maneesh Rai R. Shreyas PU Prakash Saxena Sourjya Banerjee Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study
description	Abstract Domperidone, ondansetron and olanzapine can prolong the QT interval. The clinical use of combinations of these drugs is not uncommon. Our study aimed to determine the presence of any QTc prolonging effect of the combination when used as antiemetic in patients receiving cancer chemotherapy. We carried out a prospective, observational study of patients with malignancy who were to receive domperidone, ondansetron and olanzapine-containing antiemetic regimen. Electrocardiograms were recorded before and during the administration of antiemetics, for three consecutive days. A blinded assessor determined the QTc interval using Bazett and Fridericia formulae. Thirty-six patients completed the study; 23 (63.9%) were females. There was a statistically significant change in QTc with time (Fridericia, χ2(4) = 15.629, p = 0.004; Bazett, χ2(4) = 15.910, p = 0.003); QTc on Day 1 was more than that during baseline (p < 0.001); these differences were significant in females (Fridericia, χ2(4) = 13.753, p = 0.008; Bazett, χ2 (4) = 13.278, p = 0.010) but not in males (Fridericia, χ2 (4) = 4.419, p = 0.352; Bazett, χ2(4) = 4.280, p = 0.369). Two female patients had an absolute QTc prolongation (Bazett correction) of > 500 ms. However, no clinically significant adverse events occurred. The findings show that QTc prolongation is a concern with olanzapine alone and in combination with domperidone and ondansetron, and needs to be investigated further.
format	article
author	Ashwin Kamath K. Maneesh Rai R. Shreyas PU Prakash Saxena Sourjya Banerjee
author_facet	Ashwin Kamath K. Maneesh Rai R. Shreyas PU Prakash Saxena Sourjya Banerjee
author_sort	Ashwin Kamath
title	Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study
title_short	Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study
title_full	Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study
title_fullStr	Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study
title_full_unstemmed	Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study
title_sort	effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on qtc interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/22863393271245d3999513d2007e8060
work_keys_str_mv	AT ashwinkamath effectofdomperidoneondansetronolanzapinecontainingantiemeticregimenonqtcintervalinpatientswithmalignancyaprospectiveobservationalsinglegroupassessorblindedstudy AT kmaneeshrai effectofdomperidoneondansetronolanzapinecontainingantiemeticregimenonqtcintervalinpatientswithmalignancyaprospectiveobservationalsinglegroupassessorblindedstudy AT rshreyas effectofdomperidoneondansetronolanzapinecontainingantiemeticregimenonqtcintervalinpatientswithmalignancyaprospectiveobservationalsinglegroupassessorblindedstudy AT puprakashsaxena effectofdomperidoneondansetronolanzapinecontainingantiemeticregimenonqtcintervalinpatientswithmalignancyaprospectiveobservationalsinglegroupassessorblindedstudy AT sourjyabanerjee effectofdomperidoneondansetronolanzapinecontainingantiemeticregimenonqtcintervalinpatientswithmalignancyaprospectiveobservationalsinglegroupassessorblindedstudy
_version_	1718391774119985152

Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study

Ejemplares similares